Literature DB >> 11901223

Cloning of CYP2J2 gene and identification of functional polymorphisms.

Lorraine M King1, Jixiang Ma, Supawon Srettabunjong, Joan Graves, J Alyce Bradbury, Leping Li, Martin Spiecker, James K Liao, Harvey Mohrenweiser, Darryl C Zeldin.   

Abstract

CYP2J2 is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that possess potent anti-inflammatory, vasodilatory, and fibrinolytic properties. We cloned and sequenced the entire CYP2J2 gene (approximately 40.3 kb), which contains nine exons and eight introns. We then sequenced the CYP2J2 exons and intron-exon boundaries in 72 healthy persons representing African, Asian, and European/white populations as part of the National Institutes of Health/National Institute of Environmental Health Sciences Environmental Genome Single Nucleotide Polymorphism Program. A variety of polymorphisms were found, four of which resulted in coding changes (Arg158Cys, Ile192Asn, Asp342Asn, and Asn404Tyr). A fifth variant (Thr143Ala) was identified by screening a human heart cDNA library. All five variant cDNAs of CYP2J2 were generated by site-directed mutagenesis and expressed in Sf9 insect cells by using a baculovirus system. The recombinant wild-type and variant CYP2J2 proteins immunoreacted with peptide-based antibodies to CYP2J2 and displayed typical cytochrome P450 (P450) CO-difference spectra; however, the Asn404Tyr and Ile192Asn variants also had prominent spectral peaks at 420 nm. The ability of these variants to metabolize arachidonic acid and linoleic acid was compared with that of wild-type CYP2J2. Three variants (Asn404Tyr, Arg158Cys, and Thr143Ala) showed significantly reduced metabolism of both arachidonic acid and linoleic acid. The Ile192Asn variant showed significantly reduced activity toward arachidonic acid only. The Asp342Asn variant showed similar metabolism to wild-type CYP2J2 for both endogenous substrates. Based on these data, we conclude that allelic variants of the human CYP2J2 gene exist and that some of these variants result in a P450 protein that has reduced catalytic function. Insofar as CYP2J2 products have effects in the cardiovascular system, we speculate that these variants may be functionally relevant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901223     DOI: 10.1124/mol.61.4.840

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

1.  Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide.

Authors:  Bin Xiao; Xuguang Li; Jiangtao Yan; Xuefeng Yu; Guangtian Yang; Xiao Xiao; James W Voltz; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

2.  Association of CYP2J2 gene polymorphisms with ischemic stroke.

Authors:  Qing Li; Jian-Hua Zhao; Peng-Ju Ma; Lin-Lin Su; Sheng-Bo Tao; Si-Bei Ji
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms.

Authors:  Tong Lu; Dan Ye; Xiaoli Wang; John M Seubert; Joan P Graves; J Alyce Bradbury; Darryl C Zeldin; Hon-Chi Lee
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

4.  CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Craig R Lee; Kari E North; Molly S Bray; David J Couper; Gerardo Heiss; Darryl C Zeldin
Journal:  Pharmacogenet Genomics       Date:  2007-05       Impact factor: 2.089

5.  Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine.

Authors:  Valérie Clermont; Alexia Grangeon; Azemi Barama; Jacques Turgeon; Michel Lallier; Jacques Malaise; Veronique Michaud
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

6.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Authors:  Dorit S Berlin; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

7.  Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia.

Authors:  Nicole Y Marden; Eva Fiala-Beer; Shi-Hua Xiang; Michael Murray
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

Review 8.  Roles of the epoxygenase CYP2J2 in the endothelium.

Authors:  Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-06       Impact factor: 3.072

9.  Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population.

Authors:  Laxi Zhang; Hu Ding; Jiangtao Yan; Rutai Hui; Wei Wang; Grace E Kissling; Darryl C Zeldin; Dao Wen Wang
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

10.  Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

Authors:  Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.